Squarepoint
TEVA icon

Squarepoint’s Teva Pharmaceuticals TEVA Stock Holding History

Squarepoint’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.1M Sell
502,300
-516,700
-51% -$16.6M 0.02% 848
2025
Q4 		$31.8M Buy
1,019,000
+214,200
+27% +$5.28M 0.03% 560
2025
Q3 		$16.3M Buy
804,800
+341,600
+74% +$6M 0.02% 847
2025
Q2 		$7.76M Sell
463,200
-189,800
-29% -$3.06M 0.01% 1208
2025
Q1 		$10M Buy
653,000
+75,900
+13% +$1.36M 0.01% 1025
2024
Q4 		$12.7M Buy
577,100
+482,000
+507% +$8.77M 0.01% 1009
2024
Q3 		$1.71M Buy
+95,100
New +$1.66M ﹤0.01% 2179

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Squarepoint's TEVA Position: Q1 2026 in Review

Squarepoint increased its Teva Pharmaceuticals (TEVA) stake by 19% in Q1 2026, buying an estimated $859K and bringing the position to 167,580 shares worth $5.05M. The position accounts for 0.01% of the portfolio, ranked #1497.

Squarepoint first reported a position in TEVA in Q3 2017 and has held it in 25 quarters since. The position peaked at $10.2M in Q1 2025. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Squarepoint held 167,580 shares of Teva Pharmaceuticals worth $5.05M as of Q1 2026.
  • Squarepoint bought 26,714 Teva Pharmaceuticals shares in Q1 2026, an estimated $859K.
  • Teva Pharmaceuticals made up 0.01% of Squarepoint's portfolio in Q1 2026, its #1497 holding.
  • Squarepoint first reported a position in Teva Pharmaceuticals in Q3 2017 and has held it in 25 quarters since.
  • Squarepoint's Teva Pharmaceuticals position peaked at $10.2M in Q1 2025.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.